pharmaphorum

SEPTEMBER 23, 2021

Development of the shot eventually fell behind mRNA rivals from BioNTech and Moderna, and Imperial eventually pivoted its efforts to development of possible boosters directed at emerging variants based on its self-assembling RNA (saRNA) platform. billion takeover of Translate Bio and $470 million acquisition of Tidal Therapeutics.

Vaccines 52

Vaccines Immunization 52

pharmaphorum

JULY 7, 2022

The headline readout was from Cohort 1 of its ENDEAVOR trial – in 20 subjects aged four to seven – which showed a significant improvement compared to controls at one year on the North Star Ambulatory Assessment (NSAA) scale compared to a matched control group.

FDA 57

FDA 57

pharmaphorum

JUNE 2, 2021

This sudden increase is due to reports of rare blood clots in recipients of the COVID-19 vaccines developed by AstraZeneca and more recently Johnson & Johnson. risk of developing blood clots with the contraceptive pill, with the ~0.0003% risk of blood clots with the AstraZeneca vaccine. Author Bio. HCPs compared the ~0.1%

Vaccines 100

Vaccines Hospitals 100

PharmaShots

MAY 29, 2023

The headline story then, as it has been lately, is one of sizeable gains for Mainland China and continuing incremental loss of share for the United States, which reflects a transformational rebalancing of scientific and scholarly contributions at the top level through the globalization of the research enterprise. in 2018 to a 4.7%

40

40

pharmaphorum

OCTOBER 1, 2020

The 3 rd CAR-T approval recently hit the headlines for Kite Pharma in mantle cell lymphoma. Due to this clear clinical and commercial success, the oncology field has become saturated with companies with the hope to develop a cure… but are you aware of the new CAR-T movement beyond oncology?

Medical Schools 52

Medical Schools Hospitals 52

pharmaphorum

FEBRUARY 16, 2021

But it’s the appointment of Slaoui as chief scientific advisor that’s attracting headlines, with an R&D approach that looks to be inspired by his time in charge of research at GlaxoSmithKline. Centessa has a similar approach, with each biotech working almost autonomously on a project already validated and ready for further development.

Vaccines 57

Vaccines Pharmaceutical Companies Pharmaceutical Companies 57